Washington (AFP) July 7, 2021
US biotech firm Moderna said Wednesday it had dosed its first participants in a human study of an mRNA vaccine that targets multiple strains of influenza. The company intends to recruit 180 adults in the United States for the Phase 1/2 portion of the trial to evaluate the safety and strength of immune response to the shot, called mRNA-1010. It is based on the same messenger ribonucleic (
http://dlvr.it/S3Nlcm